ARGENX SE

(MT Newswires) -- European equity investors were cautiously optimistic on Wednesday after data showed that annual inflation for the Euro area declined to 10.0% in November from 10.6% in October. American depositary receipts of European stocks were trading 0.27% higher at 1,084.47 on the S&P Europe Select ADR Index in morning trading.

In continental Europe, the gainers were led by biopharmaceutical company argenx (ARGX) and pharmaceutical company Ascendis Pharma (ASND), which rose 5.7% and 3.5% respectively. They were followed by hotel booking site trivago (TRVG) and biopharmaceutical company Cellectis (CLLS), which increased 3% and 2.8% respectively.

The decliners in continental Europe were led by financial services company Credit Suisse Group (CS) and biotech firm Forward Pharma (FWP), which fell 4.4% and 4.1% respectively. They were followed by pharmaceutical company Sanofi (SNY) and biopharmaceutical company Genfit (GNFT), which lost 3% each.

In the UK and Ireland, the gainers were led by pharmaceutical company Avadel Pharmaceuticals (AVDL) and biopharmaceutical company NuCana (NCNA), which climbed 11% and 10% higher respectively. They were followed by biopharmaceutical company Adaptimmune Therapeutics (ADAP) and software firm Endava (DAVA), which were up 5.7% and 5.4% respectively.

The decliners in the UK and Ireland were led by biopharmaceutical company Verona Pharma (VRNA) and cruise line operator Carnival (CUK), which dropped 2.4% and 1.4% respectively. They were followed by communications group WPP (WPP) and pharmaceutical company GSK (GSK), which were down 1.1% and 1% respectively.